We are a research group for pediatric cancer treatment!We are a research group for pediatric cancer treatment!

About childhood cancer

It is the most common cause of disease death in children, and is characterized by its difficulty in early detection and its rapid progression.

Childhood cancer is a general term for cancers that affect children. The number of pediatric cancers in Japan is about 2,500 per year, and it is the most common cause of death among children. Unlike adult cancers, childhood cancers are not caused by lifestyle factors. Most of them are blood cancers (leukemia, lymphoma, etc.) or solid tumors (brain tumor, neuroblastoma, renal tumor, etc.). It is characterized by the fact that it is difficult to detect symptoms early, and that the cancer progresses quickly and spreads easily throughout the body.

What is the Japan Childhood Cancer Research Group (JCCG)?

A research group for pediatric cancer treatment by medical experts nationwide.

JCCG (Japan Pediatric Cancer Research Group) was established as an NPO in December 2014 by bringing together medical experts from all over Japan to research the best pediatric cancer treatment. Almost all university hospitals, pediatric hospitals, general hospitals, and more than 200 facilities in Japan that research pediatric cancer treatment participate in JCCG.

Importance of childhood cancer treatment

What is important for pediatric cancer treatment is correct diagnosis through image diagnosis, genetic diagnosis, and pathological diagnosis, and all-Japan multicenter joint research.

JCCG aims to provide the best pediatric cancer treatment based on correct diagnosis by collaborating and sharing information among medical professionals nationwide and conducting group studies and central diagnosis.


Working together with you to promote clinical research with the world's greatest enthusiasm

Hello to all JCCG members and supporters. I am Adachi, Department of Human Health Sciences, Kyoto University. I will do my best to promote pediatric cancer clinical research by making use of my experience of being involved in the founding period of JCCG together with former President Osamu Mizutani and former Steering Committee Chairman Masahiro Fukuzawa. Dr. Tsugumichi Koshinaga, chairman and vice-chairman of the Steering Committee, Dr. Takashi Taga, chairman of the Steering Committee of the Hematology and Oncology Subcommittee, and Dr. Tatsuro Tajiri, chairman of the Steering Committee of the Solid Tumor Subcommittee. I am determined to work together with all the doctors to further develop pediatric cancer clinical research.

JCCG was officially started as an NPO in April 2015 by combining Solid Tumor Joint Organization and JPLSG (Japan Pediatric Leukemia and Lymphoma Research Group). Participation of almost all Japanese university hospitals, pediatric hospitals, general hospitals, pediatric cancer central institutions, all pediatric cancer core hospitals, and pediatric hematology and cancer training facilities specializing in pediatric cancer treatment and research In addition, experts in fields related to pediatric cancer, such as pediatrics, pediatric surgery, neurosurgery, orthopedics, radiology, pathology, head and neck surgery (otolaryngology), biostatistics, and basic researchers rallying.

In order to conduct high-quality clinical trials, it is essential to establish a central diagnostic system for immunodiagnosis, pathological diagnosis, imaging diagnosis, etc., a central data center, a tumor sample storage system, and a genome analysis system. To do so, the support of clinical research managers, data managers, and ethics experts is also important.

JALSG (Adult Leukemia Treatment Collaborative Research Organization) and JCCG joint clinical trials have been started mainly for acute lymphoblastic leukemia (ALL), and clinical trials for AYA (young adolescent adults) generation will also be conducted in the field of solid tumors in the future. It is becoming more and more important, and I think that international joint clinical trials that have been started for ALL, liver tumors, and germ cell tumors will be activated not only in Europe and the United States but also in Asia.

The social environment surrounding pediatric cancer, such as the declining birthrate and aging population and the pediatric specialist system, is by no means optimistic. But we believe that our enthusiasm is the best in the world.

In addition, I am committed to fostering many medical professionals (nurses, public health nurses, midwives, clinical laboratory technologists, physical therapists, occupational therapists, medical physicists, clinical research managers, etc.) at Kyoto University Human Health. In the future, we would like to work closely with doctors and medical professionals. I would like to conclude my greetings by thanking the patients, their families, regular members, hospital members, pediatric cancer medical personnel, secretariat staff, and volunteers for their continued support.

We appreciate your continued support and cooperation for JCCG.

President of JCCG Manabe Atsushi

President of JCCG
Manabe Atsushi